TRVI
Trevi Therapeutics Inc
14.70$
+1.5%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -6.8% | -12.1% | -6.0% | -6.6% | +60.9% | -3.5% | +94.7% | -4.3% | -3.0% | -7.2% | +84.0% | |
| – | -6.8% | -12.3% | -6.0% | -6.6% | +62.5% | -3.5% | +96.2% | -4.3% | -3.3% | -8.1% | +84.9% | |
| – | +24.8% | -57.4% | -6.1% | +23.8% | +112.4% | -43.2% | +504.2% | -51.4% | -66.7% | +2.6% | +179.7% | |
| – | -6.6% | -12.2% | -4.6% | -5.8% | +64.3% | -4.1% | +97.5% | -4.4% | -3.4% | -8.8% | +85.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +9.1% | -9.2% | +22.7% | +30.2% | +13.3% | -33.0% | +30.5% | -2.8% | +6.6% | -26.6% | +20.5% | |
| – | +12.6% | -9.4% | +28.0% | +35.1% | +15.2% | -34.7% | +34.6% | -2.2% | +7.8% | -27.0% | +22.8% | |
| – | +4.8% | +5.2% | -4.0% | -3.9% | -4.0% | -3.2% | +3.6% | +3.5% | +3.7% | +3.6% | +3.5% | |
| – | +44.0% | +16.7% | -28.5% | +6.8% | +111.5% | -58.4% | +109.3% | -8.9% | +44.4% | -43.4% | +39.9% | |
| – | -7.9% | -12.4% | -8.5% | -10.9% | +69.0% | -0.2% | +99.6% | -4.4% | -3.4% | -6.1% | +86.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.2% | +0.0% | +1.5% | +0.0% | +4.9% | +10.9% | +10.8% | +11.3% | +0.3% | +0.1% | +7.6% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.